Global Biologics Manufacturing Market 2018-2022

About Biologics

Biologics, biopharmaceutical, biologic drugs, or biological drugs refer to drugs that are extracted, synthesized, and manufactured from biological material derived from living sources, such as humans, plants, and animals. Biologics manufacturing refers to the production of such drugs.

The analysts forecast the Global Biologics Manufacturing Market to grow at a CAGR of 9.11% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the biologics manufacturing market. To calculate the market size, the report considers the cost incurred for in-house manufacturing of biologics and the revenue generated by contract manufacturers of biologics across the globe.

The market is divided into the following segments based on geography:

Americas

APAC

EMEA

The report, biologics manufacturing market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors

Amgen

F. Hoffmann-La Roche

Johnson & Johnson

Merck & Co

Pfizer

Market drivers

Introduction of new biologic drugs for treating diseases

For a full, detailed list, view the full report

Market challenges

High cost of branded drugs is deterring market growth

For a full, detailed list, view the full report

Market trends

Rise in partnerships between traditional biopharma companies and biotechnology startups

For a full, detailed list, view the full report

Key questions answered in this report

What will the market size be in 2022 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the Key vendors in this market space?

What are the market opportunities and threats faced by the Key vendors?

What are the strengths and weaknesses of the Key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.

PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 05: MARKET SIZING

Market definition

Market sizing 2017

Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 07: MARKET SEGMENTATION BY TECHNOLOGY

Segmentation by technology

Comparison by technology

In-house – Market size and forecast 2017-2022

Outsourced – Market size and forecast 2017-2022

Market opportunity by technology

PART 08: MARKET SEGMENTATION BY PRODUCT

Segmentation by product

Comparison by product

Biologics – Market size and forecast 2017-2022

Biosimilars – Market size and forecast 2017-2022

Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation

Regional comparison

Americas – Market size and forecast 2017-2022

EMEA – Market size and forecast 2017-2022

APAC – Market size and forecast 2017-2022

Key leading countries

Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 13: MARKET TRENDS

Rise in partnerships between traditional biopharma companies and biotechnology startups

Growing outsourcing of biologics manufacturing

Increase in FDA approvals for new biologics products

PART 14: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 15: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen

F. Hoffmann-La Roche

Johnson & Johnson

Merck & Co.

Pfizer

PART 16: APPENDIX

List of abbreviations

List of Exhibits

Exhibit 01: Related market
Exhibit 02: Market characteristics
Exhibit 03: Market segments
Exhibit 04: Market definition - Inclusions and exclusions checklist
Exhibit 05: Market size 2017
Exhibit 06: Validation techniques employed for market sizing 2017
Exhibit 07: Global – Market size and forecast 2017-2022 ($ bn)
Exhibit 08: Global – Year-over-year growth 2018-2022 (%)
Exhibit 09: Five forces analysis 2017
Exhibit 10: Five forces analysis 2022
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2017
Exhibit 17: Technology – Market share 2017-2022 (%)
Exhibit 18: Comparison by technology
Exhibit 19: In-house – Market size and forecast 2017-2022 ($ bn)
Exhibit 20: In-house – Year-over-year growth 2018-2022 (%)
Exhibit 21: Outsourced – Market size and forecast 2017-2022 ($ bn)
Exhibit 22: Outsourced – Year-over-year growth 2018-2022 (%)
Exhibit 23: Market opportunity by technology
Exhibit 24: Product – Market share 2017-2022 (%)
Exhibit 25: Comparison by product
Exhibit 26: Biologics – Market size and forecast 2017-2022 ($ bn)
Exhibit 27: Biologics – Year-over-year growth 2018-2022 (%)
Exhibit 28: Biosimilars – Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Biosimilars – Year-over-year growth 2018-2022 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Global – Market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ bn)
Exhibit 35: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 36: EMEA – Market size and forecast 2017-2022 ($ bn)
Exhibit 37: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 38: APAC – Market size and forecast 2017-2022 ($ bn)
Exhibit 39: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Amgen: Overview
Exhibit 48: Amgen – Business segments
Exhibit 49: Amgen – Organizational developments
Exhibit 50: Amgen – Geographic focus
Exhibit 51: Amgen – Key offerings
Exhibit 52: F. Hoffmann-La Roche: Overview
Exhibit 53: F. Hoffmann-La Roche– Business segments
Exhibit 54: F. Hoffmann-La Roche – Organizational developments
Exhibit 55: F. Hoffmann-La Roche– Geographic focus
Exhibit 56: F. Hoffmann-La Roche– Segment focus
Exhibit 57: F. Hoffmann-La Roche – Key offerings
Exhibit 58: Johnson & Johnson: Overview
Exhibit 59: Johnson & Johnson– Business segments
Exhibit 60: Johnson & Johnson – Organizational developments
Exhibit 61: Johnson & Johnson – Geographic focus
Exhibit 62: Johnson & Johnson – Segment focus
Exhibit 63: Johnson & Johnson – Key offerings
Exhibit 64: Merck & Co.: Overview
Exhibit 65: Merck & Co. – Business segments
Exhibit 66: Merck & Co. – Organizational developments
Exhibit 67: Merck & Co. – Geographic focus
Exhibit 68: Merck & Co. – Segment focus
Exhibit 69: Merck & Co. – Key offerings
Exhibit 70: Pfizer: Overview
Exhibit 71: Pfizer – Business segments
Exhibit 72: Pfizer – Organizational developments
Exhibit 73: Pfizer – Geographic focus
Exhibit 74: Pfizer – Segment focus
Exhibit 75: Pfizer – Key offerings

Executive Summary

New Report Released: - Global Biologics Manufacturing Market 2018-2022

The author of the report recognizes the following companies as the key players in the global biologics manufacturing market: Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Merck & Co, and Pfizer.

Commenting on the report, an analyst from the research team said: “One trend affecting this market is the rise in partnerships between traditional biopharma companies and biotechnology startups. The significant growth of the biologics industry and biotech companies in the past few years has encouraged several major traditional biopharma companies to collaborate with biotechnology startups to develop novel biologics drugs.”

According to the report, one driver influencing this market is the introduction of new biologic drugs for treating diseases. There is a growing demand for biologics for effective treatment of diseases as synthetic drugs have several limitations.

Further, the report states that one challenge affecting this market is the high cost of branded drugs is deterring market growth. A key factor restraining the growth of the global biologics manufacturing market is the high cost of medication.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.